Deals
Viatris Agrees To Buy Pacira For $36.50 A Share, A $1.65 Billion Bet On Non-Opioid Pain Drugs
The all-cash tender offer adds Exparel and Zilretta, with a $62 million termination fee payable by Pacira in specified cases.
Deals
The all-cash tender offer adds Exparel and Zilretta, with a $62 million termination fee payable by Pacira in specified cases.
SEC Filings
The designation covers late-line metastatic castration-resistant prostate cancer; Vir and Astellas co-develop the drug.
Deals
The $10.50-a-share cash offer is unchanged, and Amendment No. 3 to the Schedule TO moves the expiration out eight days.
SEC Filings
A Schedule 13G lists 1,708,659 shares and says none were bought to influence control of the bank holding company.
SEC Filings
The annual proxy shows bonuses at 180% of target, a board shrinking to seven and a request for more equity-plan room.
Earnings
The clinical research company will hold a webcast on October 28, with a replay posted about an hour after the call ends.
Earnings
The gold developer reported a $36.0 million third-quarter loss and said professional fees tied to the Donlin Gold purchase will stay high into early fiscal 2027.
Earnings
The company will hold a webcast call at 8:00 am ET the same day, with a replay running to November 12.
Deals
Medtronic's calculated values would have produced a ratio above the upper limit, so the offer's terms were set at the cap.
SEC Filings
The company took blocks in the Campos, Santos and Ceará basins, adding more than 18,000 km² to its exploration portfolio, it said.
Earnings
Med Tech sales rose 13.2% in the fiscal first quarter, and the company reiterated its full-year outlook ahead of a November 2 CEO handover.
SEC Filings
Eric Honroth, a Getinge executive, takes over November 2 from retiring CEO Jim Clemmer, with equity awards and severance terms set in an 8-K.